Pod Insights a16z Podcast CRISPR 2.0 and the Future of Gene Therapies About this episode To download this deck, sign up for the a16z Bio Newsletter here: https://pages.a16z.com/EngineeringtheGenome. Deck.html
Technology's ability to rewrite our genetic code is becoming one of the most powerful therapeutic arsenals of all time. We’ve gone from small molecules, to antibodies, to using biological machinery itself as we engineer our genomes to treat diseases. This is a huge paradigm shift, as these "living medicines" have given us the power to precisely target, eliminate, and even potentially cure disease—with a single dose of a drug.
In this talk, a16z bio deal partner Andy Tran walks us through the scientific developments and industry tailwinds that are bringing us into the new era of gene therapies, explaining the technological breakthroughs that advanced us from early gene therapy techniques, to using CRISPR as an engineering platform (CRISPR 2.0), and where it's going next. Along the way, Tran shares the challenges that need to be met in order to bring these therapies to as many patients as possible, as well as the enormous potential opportunities for startups in the space.
Transcript 0:15 Speaker 0 Hello, everyone. My name is Andy Tran, and I'm a partner on the A16Z bioinvesting team. What I want to spend time to talk about is one of the most important shifts impacting medicine today. Specifically on how technologies used to rewrite our genetic code is becoming one of the most powerful therapeutic arsenals of all time, with massive new progress, also bring with it an entire new set of challenges and opportunities. In this talk, we'll walk through some of the key tailwinds driving innovations in this space, as well as go through some of the biggest hurdles keeping this technology from reaching more patients. More importantly, we'll be sure to dive in potential zones of opportunity to tackle these very challenges and also touch upon some of the key ingredients that we love to look for in companies striving to make a big impact in this space.
1:03 Speaker 0 So we're really in this new era of therapeutics when our medicines are more powerful and complex than ever before. We've gone from small molecules of a few dozen atoms to full protein biologics and antibodies to this unprecedented complexity of essentially using biological machinery to engineer our genomes to cure diseases. Of course, this is certainly a big paradigm shift and very exciting, as these technologies have given us the power to precisely target and eliminate the origin of disease, as well as be very curative with just a single dose of the drug. And to be clear, this is definitely not all theory. Recent clinical translation of these drugs have produced four FDA-approved cures for patients with these gene therapies. These breakthroughs of the past two years have really been an important milestone for the entire history of medicine.
1:52 Speaker 0 More excitingly, the most recent two approvals, Luxterna for a form of congenital blindness, as well as logenzma for spinal muscular atrophy, have been actual in vivo gene therapies in which these complex medicines are sent to combat the genetic mutation directly inside the body. I think even more fascinating as we look into this entire landscape, we're really just at the beginning of this frontier, as there are about two dozen more gene therapies that are selected to just have phase three trials in this year alone. Peering a bit further into the clinical pipeline, we're expecting at least 10 to 20 gene therapy approvals per year by the end of the decade. That's an order of magnitude more of these one and done cures than we have now, every single year. Perhaps unsurprisingly, the excitement and promise of these breakthroughs has really created some of the biggest opportunities for startups working on these genetic medicines.
2:45 Speaker 0 In fact, taking a look at the past several years, some of the largest biotech exits have been from companies developing these gene therapies. So as you look at the pace of innovation continually accelerating and the market landscape and regulatory environments continue to get familiar with this new modality, we become even more excited about the extraordinary opportunity that this field brings for the entire biotech industry. So I guess to really appreciate and understand this technology shift, perhaps it's worth revisiting how we got here. After decades of promise, gene therapy has now become one of medicine's most powerful therapeutic modalities, but it didn't really start out this way. In fact, early approaches were pretty rudimentary. So on the onset, gene therapy from the start was just simple transgene addition, in which we were essentially jamming healthy copies of a gene into a disease cell.
3:36 Speaker 0 The hope here is that these healthy copies can produce enough functional proteins to compensate for the mutated gene. The problem with this method is that it never really removes the root cause mutation. And unfortunately, through tragic learnings from harsh early clinical trial realities, scientists and physicians agree that jamming in foreign genes at random places without really fixing the root cause is not a viable strategy for therapy. The first big shift in the space occurred when we started progressing to focus on making proteins that can target and cut the source of the mutated gene. This happened in the form of double-stranded breaks. The first tools created for this, meganucleases, zinc fingers, and talons worked, but were pretty clunky, expensive, and laborious to make.
4:31 Speaker 0 But nonetheless, it really did lay the right foundation and proof of concept. Of course, the most exciting development in this category here was certainly when we got our lucky break from nature in the discovery of the CRISPR-Cas9 nuclease. This was definitely unprecedented for the field because it was such an elegant and efficient system for genome editing. You can actually program a simple RNA strand to target most genomic locations. Compared to old tools, engineering was cut down from few months to a matter of weeks or days. The early wave of CRISPR-Cas9, though, was definitely not perfect, and its double-stranded break mechanism was also muddled with up targets. So in reality, it was more like the targeted damage or sloppy cutting as represented by this artistic rendition. But nonetheless, as a tool, it was a key building block to a future of more scalable and programmable genome engineering.
5:22 Speaker 0 RD at that point definitely became much more iterable, and the entire scientific community adopted this technology. So the latest generation of CRISPR tools coming online is what really is pushing us into the realm of precision genome editing. So not only have these tools been better optimized in terms of efficiency and precision, refined by the massive scientific and engineering community, but also people building new functionality. As we will see, clean precision editing was simply just the very start. To really understand this landscape even further, when we talk about CRISPR now, it's not just the Cas9 nuclease. There is an entire ecosystem of CRISPR proteins that really build out the genome engineering toolbox. Some cast nucleases are much smaller, come from less immunogenic strains, are more precise, or have new mechanisms altogether.
6:11 Speaker 0 Clearly, we are just at the beginning of building out this toolbox. So taken in total, instead of just this pair of molecular scissors that everyone talks about, the biggest recent shift in the field is this push towards making CRISPR a search engine platform of the cell. CRISPR has become the molecular infrastructure in which new genomic targeting technologies are built. Once the catalytic cutting domains responsible for these double-stranded breaks are inactivated, we can attach whatever new payload or new molecular tools that people can make to manipulate the genome. Many powerful new applications in genome engineering take the CRISPR-CAS proteins as a blueprint and replace it with other protein domains that can manipulate the genome in new ways. I think to put this more concretely, it is this new CRISPR 2.0 era that really allows us to manipulate the genome in a huge range of dimensions that are fundamentally not possible before.
7:05 Speaker 0 Gene editing clearly was just a start. So for instance, focusing on a few applications, we can replace the catalytic cutting domains with CRISPR activators and repressors to push genes into overdrive or repress them directly at the source. Scientists have even developed deaminases that can edit the genome at a single base pair resolution. This limit of precision actually opens the door for addressing an entire field of devastating SNP-based genetic diseases that were previously untreatable before. We can even now directly target and edit RNA bases, opening up the entire field of transcriptomic editing. But even these tools are just a start. There's a wide array of dimensions and even wild applications like imaging that use CRISPR as a platform layer. I think the most exciting part of this platform is that every few months or even a few weeks now, we see powerful new tools that are built atop this CRISPR system that unlocks fundamentally new engineering possibilities.
8:01 Speaker 0 The beauty here is that new use cases are just waiting to be designed and built. So putting this all together, we really think that there's no better time to build the next generation of gene therapy companies. For us in A16Z Bio, one of the most exciting things is when these cutting-edge scientific breakthroughs start to transition into an engineerable platform, paving the way for something that can be democratized and broadly built upon. And you could definitely see this trend happening with specifically the latest wave of CRISPR innovation. Because of this simplicity and ease of iteration of this engineering platform, there's been an unprecedented developer community that continues to refine and build new superpowers that catalyze the entire field. I think more importantly, these technologies are starting to be translated to breakthroughs that are approved, commercialized, and administered to patients, establishing a robust clinical and commercial precedent for new entrants to the space.
8:58 Speaker 0 Adding even more grease to the innovation machine. This past year we've seen FDA and CBR leaders drum up plans to make a big push on assessing new cell and gene therapies, as well as introduce new guidance on accelerated approvals for these new areas of product development. All these factors together really drive towards a market that is constantly growing with even more patients that are desperately waiting, putting us squarely in this perfect moment for gene therapy innovation. So, however, exciting the prospects of these powerful new drugs may seem, it does come at the expense of added layers of complexity. Not only do we have to continue to innovate and refine the science, but also develop the engineering infrastructure downstream, the value chain to support, manufacture, and ultimately deliver these tailored cures to patients.
9:47 Speaker 0 However, the beauty Is if we can solve these challenges, we can open a massive floodgate of breakthrough treatments for patients and get one step closer to eradicating the most devastating diseases in our lifetime. So we really see a couple of core challenges that are keeping these cures from the patient. Firstly, getting these complex medicines into the target organ and ultimately the cell that you want is no trivial feed. You must also do so in a way that minimizes the body, having any major immune responses that can neutralize the effect or worse, cause any lethal side effects. Once it is inside the cell, we have to ensure the precision of the genomic targeting to prevent any unintentional collateral damage to the rest of your healthy genome. And of course, we have to optimize the efficiency and ultimately potency of the drug without having to overload the body of unsafe concentrations of this drug.
10:39 Speaker 0 Finally, once you remedy the scientific and physiological challenges, how do we actually scale up the production of these complex, sometimes bespoke cures for hundreds of thousands to eventually millions of patients? So when we think about how to build a large scalable company to touch upon the most pressing challenges, several key areas come to mind. How do we create better delivery systems? Can we better optimize or engineer the gene editing machinery itself, developing new modalities and expand the genome engineering toolbox? Can new AI innovations help us refine our RD, make our drugs safer, or uncover new systems that allow us to harness new biological mechanisms. Lastly, can we apply the learnings from software and connected hardware and automation from our tech industry to rejuvenate a much dated manufacturing infrastructure that is pretty unprepared for these new wave of therapies?
11:30 Speaker 0 Of course, this is by no means an exhaustive list, but the hope is that it can inspire new ideas. The beauty of these key areas is that because they're so core to the industry and important for every drug, one can imagine creating massively scalable and valuable companies for the broader gene therapy ecosystem. So delivery is undoubtedly one of the central components of every single gene therapy, and arguably one of the most valuable challenges to tackle. It doesn't matter how great the gene therapy is if it never really gets inside the cell. Currently, most delivery vectors are plagued with low organ level precision, low efficiency, and pretty high immunogenicity. To jump in, probably the natural place to start is on the AV side, as these adenoassociated viruses are the only clinically approved vectors so far for gene therapy.
12:18 Speaker 0 But it's hardly the no-brainer solution. Problem is, immunogenicity is still a huge challenge, and therefore most of these therapies are limited to the blood and few immune privileged organs. And this is actually not surprising when you take a look at the proved drugs or clinical trials in the space. AAV also cannot be reduced because of the formation of neutralizing antibodies, or patients with pre-existing immunity can't even use them. Package size even may be limited. Startups on this front are working on developing novel platforms for CAPSA discovery and engineering. So think about high throughput direct evolution and silical machine learning based approaches to develop vectors with lower immunogenicity, programmable tropism, or exploring alternative viral species altogether.
13:03 Speaker 0 There are also many clever new biological systems made to mask AV from the immune system. On the nonviral side, there are potential solutions from a wide array of materials from lipid nanoparticles, various chemical polymers, exosomes, and even other systems that have some biomimetic functionality. In addition to being redosable, some of these solutions are less complex and costly to manufacture. For some application and diseases easier to target organs, like the liver, for instance, this might be enough. For other diseases, though, compared to viruses, in vivo targeting of certain organ systems, you know, might be tougher and unpacking kinetics might be slow. So there's a lot of optimization and targeting moities that can be engineered there. Lastly, for a lot of the ex vivo cell therapies that can take advantage of delivery outside the body, startups have been working on various technologies and hardware that can disrupt the cell membrane in mass.
13:58 Speaker 0 Some of these membrane disruption technologies like electroparation or other fluidic based disruption techniques allow for rapid delivery of a diverse range of materials in diverse cell types without the use of any vectors. And this is especially useful for obviating the need for potentially more immunogenic carriers and allowing for much larger cargo delivery in a much quicker timescale. The challenge here is how do we apply these technologies that inherently utilizes harsh physical forces while minimizing damage to the membrane? For more specific hardware approaches like microinjections and various microphilic devices, the question becomes how do we scale it up? So there are definitely a wide variety of potential solutions and no silver bullet here. Regardless of the type of vector that you're engineering, we believe the winners in the space are the ones that could harness a specific platform and marry it with very thoughtful optimization towards specific disease areas.
14:55 Speaker 0 So though delivery is immensely important, it is just a frontier. Once it is inside the cell, many of our current protein-based genome editing nucleases are still plagued by off-target effects, low efficiency, and side effects from the immunogenicity of the protein itself. And this is not too surprising, as our most popular CRISPR-Cas protein comes from staph or strep bacteria. As a central core of the technology is based around the nuclease itself, a lot of the solution can come from protein engineering or developing new chemical or synthetic biology tools. On the protein engineering side, there are lots of startups that are developing pretty clever and unique systems to do scalable, high-throughput protein engineering. To attack problems of precision and CRISPR, these systems are, for instance, engineering nucleases that have expanded PAM, higher specificity, binding nucleases, and optimizing other variants that may have unique properties such as smaller size, higher efficiency, and lower immunogenicity altogether.
15:54 Speaker 0 Perhaps orthogonal to protein engineering, there's a lot of creative efforts that Mary advances in synthetic biology and chemistry develop new tools that allow us to manipulate our CAS enzymes better. For instance, you can program new on-off switches to add levels of control, or even photocleavable protein domains that allow for the spatiotemporal precision of cast protein, so it can be activated by light, for instance. So, even more exciting, many companies are abandoning the conventional CRISPR platform altogether and using it as a foundational platform or search engine, if you will, to build atop new tools. These new tools that allow us to reprogram biology in fundamentally new dimensions like base editing, transcriptomic editing, epigenetic modification, et cetera, can really sidestep the initial problems CRISPR is plagued by.
16:42 Speaker 0 Furthermore, these new tools such as DNA-based editing or RNA editing, allow us to manipulate our genome in extremely high resolution precision that was never possible before. Companies developing these systems not only help improve the fundamental gene therapy toolkit, but also unlock our ability to develop new drugs to tackle a breadth of diseases that were previously untreatable before, or do so in a much safer way. These innovations in some really expand the power and breadth of our therapeutic arsenal. So aside from engineering biology, there are many things that you can do on the computational front to derive new insights that can help us or use our tools in much more powerful ways. If we think about the problems that plague our genome editing systems from a technical performance level, there are many computational efforts that can help us design better guide RNAs that have higher efficiency and precision, for instance.
17:35 Speaker 0 Machine learning-driven solutions here that learn from prior assays and allow for better guide designs, make our CRISPR system much more adept at engineering difficult to edit cell types, for instance. On the analysis side, there are groups working on algorithms that can help predict beforehand where and how CRISPR will actually interact in the genome, essentially creating a heat map of how the system is most likely to perform, or even fail. With new predictive capabilities, scientists can actually engineer new therapies that are more precise and safer, or perhaps even take advantage of these inherent flaws, thereby allowing us to harness powerful new mechanisms that were originally not possible without computation. I think orthogonally, there's a lot of exciting efforts that are developing high-throughput screening and metagenomic analysis systems that are essentially operationalizing that effort of mining for related nucleases or discovering new genome editing systems altogether.
18:32 Speaker 0 As we continue to mine new metagenomic data of new species, it's not crazy to think that perhaps even CRISPR itself is by no means the final frontier of genome engineering. The hope is that by digging up hydrothermic vents or going to geysers or even New York City subway transit systems and finding these new microbial species, we can have new genome engineering tools that have properties that ameliorate the prior flaws or have new superpowers altogether. We can think about smaller enzymes that are easier to deliver, non-immunogenic species, or novel biological mechanisms. So once you've designed the perfect gene therapy, perhaps one of the most overlooked but most existential threats to the industry is challenges in manufacturing. There's a large, hairy and deep supply chain that has to work laboriously behind the scenes to make and ultimately deliver these complex drugs to patient.
19:24 Speaker 0 As we're projecting about 50 plus gene therapies by the end of the next decade, many of our efforts will never even get delivered to the patients that need it the most if we don't solve this challenge. So on the infrastructure side, one area of innovation can come from automation. And automation can come from both a hardware side in robotics that can simply afford new. Newfound speed and scale or modular systems that let you continue to experiment and adapt new vectors and different cells. And automation can also come from the software side, in which limbs and new ways to operationalize and scale these complex processes can be operationalized in an easy-to-manage software layer. Automated track and trace and data logging are essential for safety, for instance, and having good software tools afford manufacturers and scientists to have the ability to have clear oversight on critical abilities associated with the product during critical steps.
20:18 Speaker 0 On the supply chain side, how can we have better software for digital real-time tracking of cells and clear visibility into a patient development cycle? For instance, can we have enterprise grade software and best in class cloud technology that provides chain of identity or chain of custody at scale? Connecting the supply chain and courier systems, transport condition monitoring, and electronic batch record systems are also all very key to the entire process. Apart from the infrastructure side, we can also look to nature and biology for solutions. Aside from increasing the speed and volume from the pure software and hardware side, biology can also alleviate bottlenecks by offering new avenues for much higher efficiency. New innovations in synthetic biology and genome engineering can actually allow us to have much better producer cell lines that can produce viral vectors, for instance, at much higher yields.
21:11 Speaker 0 New advances in metabolic engineering or fermentation workflows, innovative bioreactor designs, even can also aid in the early stages of producing plasmids that are better quality and higher yield. So clearly, there are many exciting angles that one can take to tackle the most pressing challenges facing the gene therapy industry. Hopefully, we can come away from this with the idea of not how much work that is left to do, but the massive room for opportunity to build new exciting companies. Furthermore, the beauty is that for a lot of these things that didn't seem like big businesses before can actually become immensely valuable now because of the nature of the rapidly growing gene therapy ecosystem, those once seemingly niche solutions for complex therapies or gradually becoming the standard part of the therapeutic value chain.
21:59 Speaker 0 There are even new gene therapy companies that are taking all the areas that we've really discussed and building these types of full-stack gene therapy companies that integrate RD, delivery system engineering, and in-house manufacturing to streamline and more finely control the development of these complex therapies. Because of these massive influx of new gene therapy treatments in the clinical pipeline, viral vector and cell manufacturing have become important core competencies, a variety of contract development and manufacturing organizations and biotech service providers. A lot of these big biotech product development giants are looking to acquire smaller companies that have deep expertise in viral vector processing. So it is clear that this trend is becoming a critical part of the entire drug development infrastructure.
22:46 Speaker 0 So when it comes time to evaluate new companies in the space, there are a couple of key components that we like to dig into. Of course, each company has its own journey, so there are definitely no right or wrong answers, but what's important is going through the idea maze to find your own earned secrets here. First, there's definitely no one size fits all modality or the best tool for the job. The ironic first world problem here that we have in this field is that the pace of innovation grants us every few months or even a few weeks a shiny new genome engineering tool. Many times, the latest, most advanced, mechanistically complex and by definition the least validated system is not the best tool if a simple CRISPR knockout, for instance, can solve your problem. There are always a variety of platforms and techniques available and no clear winner for each application.
23:37 Speaker 0 What is important is being rigorous in assessing the simplest technologies tailored for your use case. There's definitely no need to add layers of complexity to be different. So perhaps unsurprisingly, indication selection is extremely important. This is fundamental for all drug companies, of course, but perhaps even more crucial to keep in mind for gene therapy companies, simply because of how broad these platform tools are. Aside from picking an application based on understanding your modality and unmet clinical need, it is also important to go through the exercise of evaluating the appropriate balance between investing in these low-risk modest reward programs versus those with more high impact but more high risk. There's definitely no single best clinical pipeline portfolio strategy, but winners will definitely have invested ample time up front to think it through before you really jump into an initial application that defines your company.
24:31 Speaker 0 Executing a BD strategy that propels the platform is also super important. There is ample capital out there and many possible applications, given the broad applicability of these tools, and especially in the early days, it is important to take strong partnerships that are not only good deals from a financial standpoint, but also showcases unique capabilities of the platform, which ultimately helps craft the vision of the company. Another important aspect, but especially true for the non-peer therapeutic opportunities that we've discussed is thinking through whether the company is better served as a horizontal-based platform company or an integrated full stack company. Does the value of this technology come from diverse application and partnering broadly, or does the nature of the product make it better suited to be developed entirely in-house in one fully vertically integrated company?
25:23 Speaker 0 So when we think about the new era of complex medicines, now more so than ever before, interdisciplinary teams really provide the edge and the key to a successful company. This new era of companies would look much more diverse than ever before, likely requiring the skills and collaboration of molecular biologists, protein engineers, machine learning natives, data scientists, clinicians, and even manufacturing experts. And finally, the last key ingredient that we love to see, but might often be overlooked, are companies that take advantage of an engineering approach to the company. You know, this engineering mindset really runs through not only the core product or drug development, but also the entire organization. In the midst of a rapidly exciting and growing field from the science, clinical landscape, business, and regulatory, is important to be nimble and iterate quickly.
26:13 Speaker 0 So it is clear that our ability to engineer the genome is transforming the very fundamentals of medicine. As the technology, infrastructure, and economics of these drugs continue to progress, it is not too far-fetched to think of a future in which eventually many of our most devastating diseases, even more common chronic ones, can be targeted and treatable with these genome engineering tools. We really think that there has never been a more exciting time for gene therapy innovation. So if you're building a company in the space or have ideas on how to tackle these key issues, our door is always open, and we definitely love to talk. We can hopefully make this new paradigm of powerful drugs commonplace and accessible for all the patients who really need it the most. Thanks so much for listening.
Previous The Environment, Capitalism, Technology Next Of Emojis and Innovation Page updated August 25, 2026 · transcript and summary are machine-generated